Company intelligence / Profile preview

Atlas Venture

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Atlas Venture has launched over 70 biotech startups, leading to more than 25 medicines developed by its portfolio companies, over 40 IPOs, and 34 M&A exits. Its investments have resulted in several high-profile clinical outcomes and partnerships, such as Nimbus Therapeutics' $4 billion TYK2 drug licensing to Takeda and Intellia Therapeutics' entry into Phase 3 trials with a CRISPR-based therapy.

Therapeutic areas: ImmunologyMetabolic DisordersOphthalmologyInfectious DiseasesRare DiseasesOncology
Modalities: Small moleculeMonoclonal antibodyGene therapyRNA therapyRadiopharmaceuticalCRISPR-based therapy
Industry: Investors

Partnerships

Takeda (via Nimbus Therapeutics)Eli Lilly (via Versanis)Multiple Big Pharma (via portfolio companies)

Beyond the preview

Go deeper on Atlas Venture.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atlas Venture.

Explore the full profile